Noile-Immune Biotech (TSE:4893) Total Liabilities: 円79.64 Mil (As of Dec. 2025)


TSE:4893 Noile-Immune Biotech Inc TSE:4893
49 GF Score
Price 円136.00
GF Value 円4.34
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech Total Liabilities?

Noile-Immune Biotech TSE:4893 +5.43% 49 Total Liabilities is 円79.64 Mil as of Dec. 2025. GuruFocus rates TSE:4893 with a GF Score™ of 49/100 and a GF Value™ of 円4.34 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Noile-Immune Biotech's Total Liabilities for the quarter that ended in Dec. 2025 was 円79.64 Mil.

Noile-Immune Biotech's quarterly Total Liabilities increased from Jun. 2025 (円68.07 Mil) to Sep. 2025 (円73.88 Mil) and increased from Sep. 2025 (円73.88 Mil) to Dec. 2025 (円79.64 Mil).

Noile-Immune Biotech's annual Total Liabilities declined from Dec. 2023 (円91.49 Mil) to Dec. 2024 (円74.68 Mil) but then increased from Dec. 2024 (円74.68 Mil) to Dec. 2025 (円79.64 Mil).

Noile-Immune Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech Total Liabilities Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 85.72 340.42 91.49 74.68 79.64

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.32 68.07 73.88 79.64 66.28
TSE:4893
49GF Score
Noile-Immune Biotech Inc TSE:4893
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Noile-Immune Biotech's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=74.405+(0+5.234
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=79.64

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=4011.579-3931.94
=79.64

Noile-Immune Biotech's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=74.405+(0+5.234
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=79.64

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=4011.579-3931.94
=79.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of 円79.64 Mil mean?
Noile-Immune Biotech (TSE:4893) has a Total Liabilities of 円79.64 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's Total Liabilities too high?
Noile-Immune Biotech's current Total Liabilities is 円79.64 Mil. Overall, Noile-Immune Biotech has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Total Liabilities compare to VRTX and REGN?
Noile-Immune Biotech's Total Liabilities of 円79.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Total Liabilities is 円79.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.34, compared to a current price of 円136.00 — trading 3033.6% above its estimated fair value. The current Total Liabilities is 円79.64 Mil. Noile-Immune Biotech's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Total Liabilities is 円79.64 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円136.00 is trading 3033.6% above its estimated GF Value™ of 円4.34. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • Total Liabilities: 円79.64 Mil
  • GF Value™: 円4.34 vs. price of 円136.00 (3033.6% above fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
49GF Score

Get the complete analysis for TSE:4893

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円136.00
Price
円4.34
GF Value